1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. SCOPE OF STUDY
1.3. METHODOLOGY
1.4. ASSUMPTIONS & LIMITATIONS

2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW

3. MARKET DYNAMICS
3.1. DEVELOPMENT OF IMMUNOSUPPRESSANT DRUGS
3.2. MARKET DEFINITION
3.3. KEY DRIVERS
3.3.1. INCREASE IN THE NUMBER OF AUTOIMMUNE DISORDERS
3.3.2. RISE IN ORGAN TRANSPLANTATION
3.3.3. GROWTH IN THE PHARMACEUTICAL INDUSTRY
3.4. KEY RESTRAINTS
3.4.1. SIDE EFFECTS OF IMMUNOSUPPRESSANT DRUGS
3.4.2. LACK OF AWARENESS ABOUT ORGAN DONATION

4. KEY ANALYTICS
4.1. KEY INVESTMENT INSIGHTS
4.2. PORTER’S FIVE FORCE ANALYSIS
4.2.1. BUYER POWER
4.2.2. SUPPLIER POWER
4.2.3. SUBSTITUTION
4.2.4. NEW ENTRANTS
4.2.5. INDUSTRY RIVALRY
4.3. OPPORTUNITY MATRIX
4.4. VENDOR LANDSCAPE

5. MARKET BY DISTRIBUTION CHANNEL
5.1. HOSPITAL PHARMACIES
5.2. RETAIL PHARMACIES
5.3. ONLINE PHARMACIES

6. MARKET BY END-USER
6.1. ORGAN TRANSPLANTATION
6.2. AUTOIMMUNE DISORDERS
6.3. OTHERS

7. MARKET BY DRUG CLASS
7.1. CORTICOSTEROIDS
7.2. MONOCLONAL ANTIBODIES
7.3. CALCINEURIN INHIBITORS
7.4. MTOR INHIBITORS
7.5. OTHERS

8. GEOGRAPHICAL ANALYSIS
8.1. NORTH AMERICA
8.1.1. UNITED STATES
8.1.2. CANADA
8.2. EUROPE
8.2.1. UNITED KINGDOM
8.2.2. GERMANY
8.2.3. FRANCE
8.2.4. ITALY
8.2.5. RUSSIA
8.2.6. BELGIUM
8.2.7. POLAND
8.2.8. REST OF EUROPE
8.3. ASIA PACIFIC
8.3.1. CHINA
8.3.2. JAPAN
8.3.3. INDIA
8.3.4. SOUTH KOREA
8.3.5. INDONESIA
8.3.6. THAILAND
8.3.7. VIETNAM
8.3.8. AUSTRALIA & NEW ZEALAND
8.3.9. REST OF ASIA PACIFIC
8.4. REST OF WORLD
8.4.1. LATIN AMERICA
8.4.2. MIDDLE EAST & AFRICA

9. COMPANY PROFILES
9.1. ABBVIE INC
9.2. ALLERGAN PLC (ACQUIRED BY ABVIE INC)
9.3. ASTELLAS PHARMA INC
9.4. BRISTOL-MYERS SQUIBB COMPANY
9.5. CIPLA LTD
9.6. DR. REDDY’S LABORATORIES LTD
9.7. F HOFFMANN-LA ROCHE AG
9.8. GLAXOSMITHKLINE PLC
9.9. INTAS PHARMACEUTICALS LTD (ACCORD HEALTHCARE LTD)
9.10. JANSSEN PHARMACEUTICALS NV (JHONSON & JHONSON)
9.11. MYLAN NV
9.12. NOVARTIS INTERNATIONAL AG (SANDOZ)
9.13. PFIZER INC
9.14. SANOFI SA
9.15. VELOXIS PHARMACEUTICALS